Cantor Fitzgerald Initiates Coverage On Stemline Therapeutics with Overweight Rating, Announces $18 Price Target

Cantor Fitzgerald initiates coverage on Stemline Therapeutics (NASDAQ:STML) with a Overweight rating and a $18 price target.

Benzinga · 12/24/2019 11:17

Cantor Fitzgerald initiates coverage on Stemline Therapeutics (NASDAQ:STML) with a Overweight rating and a $18 price target.